Curbside Consultation in IBS: 49 Clinical Questions

Brian E. Lacy, PhD, MD

Question 38: What is Lubiprostone and When Should I Use it in my Patients with IBS? (continued)

Lucinda A. Harris, MD; Tisha N. Lunsford, MD

Lubiprostone (Amitiza [Sucampo Pharmaceuticals, Inc, Bethesda, MD]) is a bicyclic fatty acid that is a member of a new class of agents called prostones. It was approved for the treatment of chronic idiopathic constipation (CIC) in both men and women in 2006 at a dose of 24 µg twice daily, and it was approved in 2008 at a dose of 8 µg twice daily for the treatment of women with irritable bowel syndrome with constipation (IBS- C).1,2 Using a new therapy requires an understanding of the drug’s mechanism of action and metabolism. Lubiprostone is a type- 2 chloride channel…